China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New Drug (IND) filing for its in-house developed selective ATR kinase inhibitor TCC1727 by the US FDA.
ATR Kinase and TCC1727 Mechanism
ATR, namely ataxia telangiectasia and Rad-3-related protein, is a family of protein serine/threonine kinases and a core member of the DDR pathway. ATR kinase is a key factor in drug resistance of many kinds of clinical anti-tumor therapies, including platinum, gemcitabine, and PARP inhibitors. TCC1727 is a selective inhibitor of ATR kinase. By inhibiting the ATR function, TCC1727 interferes with DNA damage repair and makes cancer cells die after DNA damage.
Clinical Development and Anti-Tumor Activity
Existing data show that TCC1727, being developed to treat non-small cell lung cancer, small cell lung cancer, ovarian cancer, triple-negative breast cancer, and others, has significant anti-tumor activity in multiple tumors.-Fineline Info & Tech
